StockNews.com downgraded shares of Madrigal Pharmaceuticals (NASDAQ:MDGL – Get Rating) from a hold rating to a sell rating in a research report sent to investors on Thursday morning. Several other equities research analysts have also recently weighed in on the company. Oppenheimer increased their target price on Madrigal Pharmaceuticals from $300.00 to $350.00 in a […]
StockNews.com downgraded shares of Madrigal Pharmaceuticals (NASDAQ:MDGL – Get Rating) from a hold rating to a sell rating in a research note released on Thursday. Several other analysts have also recently commented on MDGL. Canaccord Genuity Group boosted their price target on Madrigal Pharmaceuticals from $296.00 to $336.00 and gave the stock a buy rating […]
StockNews.com downgraded shares of Madrigal Pharmaceuticals (NASDAQ:MDGL – Get Rating) from a hold rating to a sell rating in a research note released on Saturday morning. MDGL has been the topic of a number of other research reports. Oppenheimer upped their target price on shares of Madrigal Pharmaceuticals from $300.00 to $350.00 in a report […]
Madrigal Pharmaceuticals (NASDAQ:MDGL – Get Rating) had its price target increased by Oppenheimer from $300.00 to $350.00 in a research note released on Tuesday, The Fly reports. Other equities analysts have also recently issued reports about the stock. Canaccord Genuity Group raised their price target on shares of Madrigal Pharmaceuticals from $296.00 to $336.00 and […]
Jennison Associates LLC trimmed its position in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL – Get Rating) by 48.1% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 58,956 shares of the biopharmaceutical company’s stock after selling 54,544 shares during the quarter. […]